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Philip J. Bierman, James O. ArmitagePrimary central nervous system (CNS) non-
Hodgkin lymphoma can involve the brain, spinal
cord, meninges, cranial nerves, and eyes. Data from
the Central Brain Tumor Registry of the United States
indicate that approximately 2.4% of primary brain
tumors are lymphomas. Primary diffuse large B cell
lymphoma of the CNS is recognized as a distinct entity
in the latestWorld Health Organization Classification
of lymphoid tumors, although other histologic sub-
types of primary and secondary CNS lymphoma may
be seen. According to the SEER database, the median
survival of patients with primary CNS lymphoma has
doubled over the last 30 years, although the 5-year
survival is only approximately 25%. The prognosis
for those who relapse is poor.
In other situations, there can be secondary CNS
involvement at relapse, or the CNS may be involved
along with other sites in the body at the time of
diagnosis. Approximately 3% to 10% of patients
with aggressive lymphomas will relapse in the CNS
[1-5]. Some studies suggest that rituximab use may de-
crease this risk [1,2]. CNS relapses often occur while
patients are receiving treatment or within 6 months
of completing therapy. This suggests that unrecog-
nized disease was present at diagnosis [6]. The progno-
sis for these patients is also poor, andmedian survival is
often\6 months [1-5].
In this issue, Cote and colleagues [7] describe
results of a retrospective series of 32 patients who
received high-dose therapy followed by autologous
hematopoietic stem cell transplantation (AHSCT)
for CNS lymphoma. Patients received a preparative
regimen consisting of thiotepa, busulfan, and cyclo-
phosphamide because these agents achieve high
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6/j.bbmt.2011.11.006progression-free survival were estimated to be 93%
and 90%, respectively. There was only 1 transplant-
related death before day 100, and no patients had
late cognitive deficits, with a median follow-up of
slightly over 12 months.
These results are remarkable in light of the poor
outcomes described with similar patients. However,
this cohort was a heterogeneous group of patients
with both primary and secondary CNS lymphomas,
and the median follow-up was only 379 days posttrans-
plantation. A significant proportionwas transplanted in
first remission. The median age of patients with
primaryCNS lymphomawas 52 years, whereas theme-
dian age at diagnosis is 63 years for patients in theSEER
database. An analysis of prognostic factors was not
reported, although all but 2 patients were in complete
or partial remission before transplantation and no pa-
tients had a performance status $2. These patients
have the best outcomes in other reports of AHSCT
for CNS lymphoma. Most important, we do not
know the ‘‘denominator’’ of patients who were never
felt to be suitable transplant candidates because of co-
morbid conditionsor failure to respond to conventional
second-line treatments. For example, only 27 of 43
patients (63%) with relapsed and refractory CNS lym-
phoma in 1 series were able to proceed to transplanta-
tion, and only 50% were transplanted in another [8,9].
Despite these criticisms, the results of this paper
demonstrate that relapse of primary CNS lymphoma
and CNS relapse of systemic non-Hodgkin lymphoma
is not a death sentence. Although results in the ‘‘real
world’’ are unlikely to be as good, this report adds to
the growing body of literature demonstrating that
these patients may be appropriate candidates for
AHSCT and that long-term progression-free survival
is possible. This is the most important take-home
message, and we have demonstrated this at our institu-
tion [10].
What about AHSCT in first remission? Conflict-
ing results have been noted in randomized trials for
patients with other high-risk diffuse large B cell
lymphoma. Several patients in this series had both
systemic and CNS sites of lymphoma at the time of
diagnosis. There is no standard of care for these
patients. We have attempted to transplant these
patients in first remission following treatment with1
2 Biol Blood Marrow Transplant 18:1-5, 2012P. J. Bierman and J. O. Armitagestandard R-CHOP combined with high-dose metho-
trexate administered at day 14 of each cycle. The
authors state that upfront AHSCT is now their stan-
dard therapy for such patients. We agree with this
approach, although results from randomized trial are
not available.
What about upfront AHSCT for primary CNS
lymphoma? High-dose methotrexate is the backbone
of treatment for these patients. The addition of cytara-
bine or other agents may improve outcomes, although
hematologic toxicity is higher [11]. Consolidative
whole-brain radiation is also used, although this strat-
egy increases the risk of neurotoxicity, especially in
older patients. Phase II trials have investigated the
role of upfront AHSCT as another strategy for
improving the results of treatment for primary CNS
lymphoma [9,12-14]. Promising results have been re-
ported, although intent-to-treat analyses demonstrate
that 23% to 50% of patients are not able to proceed
to transplantation following induction therapy.
The IELSG-32 (http://clinicaltrials.gov/ct2/res
ults?term5IELSG-32) trial and the French PRECIS
(http://clinicaltrials.gov/show/NCT00863460) trial
are investigating the role of upfront AHSCT for pri-
mary CNS lymphoma. These trials are actually testing
whether the use of AHSCT can replace whole-brain
irradiation, because patients in both studies are ran-
domized to receive whole-brain radiation or to treat-
ment with AHSCT following initial chemotherapy.
A planned U.S. Intergroup trial will randomize
patients after initial induction treatment to receive
AHSCT or to treatment with additional cytarabine
and etoposide. All of these trials are using high-dose
chemotherapy regimens that include thiotepa. Only
3 randomized trials for primary CNS lymphoma
have ever been reported. These new trials will clarify
the role of AHSCT in the initial management of these
patients. This report by Cote and colleagues [7] has
helped to refine the role of this approach for other
patients with lymphoma involving the CNS.ACKNOWLEDGMENTS
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